Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.56 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.56 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.56 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.56 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.56 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.56 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.56 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | NAMPT | P43490 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14274234 | 0.92 | CYP17A1 (0.59) | ALDH1A1L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL2062613 | 0.87 | NAMPT (0.67) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL8770870 | 0.87 | NAMPT (0.67) | RAB9AMEN1KMT2ANPC1NAMPT | |
| SCHEMBL9646358 | 0.86 | PDK1 (0.59) | L3MBTL1RAB9AMEN1KMT2APDK1 | |
| SCHEMBL775002 | 0.86 | NAMPT (0.56) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL17526122 | 0.86 | NAMPT (0.73) | ALDH1A1RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL8738157 | 0.86 | CYP17A1 (0.51) | ALDH1A1L3MBTL1RAB9AMEN1KMT2A | |
| SCHEMBL243401 | 0.85 | CYP17A1 (0.56) | ALDH1A1MEN1KMT2ANAMPTCYP17A1 | |
| SCHEMBL13055402 | 0.84 | CYP17A1 (0.59) | ALDH1A1L3MBTL1NAMPTSMN1; SMN2CYP17A1 | |
| SCHEMBL3461792 | 0.83 | SMN1; SMN2 (0.59) | RAB9AMEN1KMT2ANPC1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111362942-B | Sophoridine derivative with multi-target anti-tumor activity and preparation method and application thereof | 天津市医药科学研究所 | 2022-07-05 | — | — | CN | claimed |
| CN-111362942-A | Sophoridine derivative with multi-target anti-tumor activity and preparation method and application thereof | 天津市医药科学研究所 | 2020-07-03 | — | — | CN | claimed |
| CN-111362942-B | Sophoridine derivative with multi-target anti-tumor activity and preparation method and application thereof | 天津市医药科学研究所 | 2022-07-05 | — | — | CN | disclosed |
| CN-111362942-A | Sophoridine derivative with multi-target anti-tumor activity and preparation method and application thereof | 天津市医药科学研究所 | 2020-07-03 | — | — | CN | disclosed |
| CN-101829602-B | Catalytic system for preparing N-Boc-aromatic amine compounds and preparation method and application thereof | ZHENZHOU TETRANOV BIOPHARM CO LTD | 2012-09-26 | — | — | CN | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| CN-101829602-A | Catalytic system for preparing N-Boc-aromatic amine compounds and preparation method and application thereof | ZHENZHOU TETRANOV BIOPHARM CO LTD | 2010-09-15 | — | — | CN | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | ALDH1A1 2151/4885L3MBTL1 1324/4885RAB9A 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.